Dr. Graff Discusses the Treatment of Prostate Cancer

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.